Stock Events

Stock Events

BioVie 

$0.3580
67
-$0.00-0.56% 16:04 Today

Statistics

Day High
0.35
Day Low
0.32
52W High
0.585
52W Low
0.14
Volume
7,363
Avg. Volume
-
Mkt Cap
3.03M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

2DecExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
-1.82
-1.39
-0.95
-0.52
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-22.12MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BIVIW. It's not an investment recommendation.
Tesla
15
TSLA
NVIDIA
13
NVDA
Amazon
11
AMZN
AMD
11
AMD

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Madrigal Pharmaceuticals
MDGL
Mkt Cap12.33B
Madrigal Pharmaceuticals is focused on developing therapies for NASH, directly competing with BioVie's liver disease portfolio.
Viking Therapeutics
VKTX
Mkt Cap3.75B
Viking Therapeutics is working on treatments for metabolic and endocrine disorders, including NASH, making it a direct competitor to BioVie.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences has a broad portfolio of liver disease treatments, including for NASH and hepatitis, competing with BioVie's offerings.
Agios Pharmaceuticals
AGIO
Mkt Cap1.99B
Agios Pharmaceuticals focuses on metabolic disorders, including those affecting the liver, positioning it as a competitor to BioVie.
Galmed Pharmaceuticals
GLMD
Mkt Cap4.34M
Galmed Pharmaceuticals is developing therapies for liver diseases like NASH, competing in the same space as BioVie.
Enanta Pharmaceuticals
ENTA
Mkt Cap396.11M
Enanta Pharmaceuticals is engaged in developing treatments for liver diseases, including NASH, directly competing with BioVie.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie has a diverse portfolio that includes treatments for liver diseases, competing with BioVie in the broader liver disease market.

About

BioVie Inc is a clinical-stage company developing drug therapies for the treatment of neurological and neurodegenerative disorders and liver disease. Its therapeutic areas include Alzheimer's, Parkinson's, Long COVID, Ascites, Longevity, and Epigenetics. In liver disease, its investigational drug candidate BIV201 (continuous infusion terlipressin) was granted FDA Fast Track status and FDA Orphan Drug designation for ascites due to all etiologies except cancer. BIV201 is being evaluated as a treatment option for patients suffering from life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.
Show more...
CEO
Cuong Viet Do
Employees
13
Country
United States
ISIN
US09074F1738

Listings

XNAS
US
BIVIW
BOATS
BOATS
BIVI.BOATS
XNAS
US
BIVI

0 Comments

Share your thoughts

FAQ

What is BioVie stock price today?▼
The current price of BIVIW is $0.36 USD — it has decreased by -0.56% in the past 24 hours. Watch BioVie stock price performance more closely on the chart.
What is BioVie stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange BioVie stocks are traded under the ticker BIVIW.
Is BioVie stock price growing?▼
BIVIW stock has risen by +11.87% compared to the previous week, the month change is a -16.74% fall, over the last year BioVie has showed a -10.5% decrease.
What is BioVie market cap?▼
Today BioVie has the market capitalization of 3.03M
When is the next BioVie earnings date?▼
BioVie is going to release the next earnings report on December 02, 2026.
What is BioVie revenue for the last year?▼
BioVie revenue for the last year amounts to 0 USD.
What is BioVie net income for the last year?▼
BIVIW net income for the last year is -22.12M USD.
How many employees does BioVie have?▼
As of September 04, 2026, the company has 13 employees.
In which sector is BioVie located?▼
BioVie operates in the Health & Wellness sector.
When did BioVie complete a stock split?▼
The last stock split for BioVie was on July 07, 2025 with a ratio of 1:10.
Where is BioVie headquartered?▼
BioVie is headquartered in CARSON CITY, United States.